Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/7/2025

Evolocumab in Primary Prevention of Cardiovascular Events

Introduction to Evolocumab Trials

  • The FOURIER trial demonstrated a 15% reduction in primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for angina, or revascularization) and 20% reduction in cardiovascular death, MI, or stroke over 2.2 years in patients with prior ASCVD, according to the American Diabetes Association 3
  • The ODYSSEY OUTCOMES trial showed a 1.6% absolute risk reduction over 2.8 years in patients with recent acute coronary syndrome, as reported by the American Heart Association 1

Current Guideline Restrictions

  • Guidelines from the American College of Cardiology consistently restrict PCSK9 inhibitors to secondary prevention or familial hypercholesterolemia, noting the absence of primary prevention data, with a strength of evidence level of A 1
  • The American Diabetes Association recommends that PCSK9 inhibitors are reserved for secondary prevention or familial hypercholesterolemia, with a moderate strength of evidence 6
  • In primary prevention populations (except familial hypercholesterolemia), the number needed to treat would be prohibitively high, according to the American Heart Association, with a low strength of evidence 6

Implications for Current Practice

  • Until VESALIUS-CV results are published, evolocumab should NOT be used in patients without prior MI or stroke, except for familial hypercholesterolemia, as recommended by the American College of Cardiology, with a high strength of evidence 6
  • Ezetimibe should always be tried before evolocumab due to lower cost and established safety, according to the American Diabetes Association, with a moderate strength of evidence 6
  • For heterozygous familial hypercholesterolemia patients age 30-75 years with LDL-C ≥100 mg/dL despite maximally tolerated statin plus ezetimibe, evolocumab may be considered, as reported by the American Heart Association, with a low strength of evidence 6